Management of Aripiprazole‑Induced Tremor

First‑Line Management: Dose Reduction

• Reducing the aripiprazole dose by approximately 50 % is recommended as the initial strategy because higher doses are linked to a greater risk of extrapyramidal symptoms, including tremor. This recommendation is supported by guideline‑type guidance. 2

Avoidance of Anticholinergic First‑Line Therapy

• Anticholinergic agents such as benztropine or trihexyphenidyl should not be used as first‑line treatment for aripiprazole‑related tremor; dose reduction or discontinuation is more effective and minimizes polypharmacy. This advice is based on expert consensus. [1][3]

Alternative Antipsychotic Selection When Ongoing Treatment Is Needed

• If continued antipsychotic therapy is required, switching to agents with a lower extrapyramidal risk—specifically quetiapine or olanzapine—is advised, acknowledging that these alternatives carry higher metabolic side‑effect potential. 1

Adjunctive Propranolol for Persistent Tremor

• When aripiprazole must be maintained at a therapeutic dose and tremor persists, adding propranolol (starting at a low dose and titrating up to a moderate range, administered two to three times daily) can be considered as an adjunctive measure. 1

Patient Populations Requiring Dose Caution

• Elderly individuals, patients with hepatic impairment, or those identified as poor metabolizers of CYP2D6 should receive lower aripiprazole doses because they have an increased susceptibility to dose‑related side effects, including tremor. 2

Discontinuation Considerations for Mood or Psychotic Disorders

• Abrupt cessation of aripiprazole is discouraged in patients being treated for bipolar disorder or schizophrenia; any discontinuation should be coordinated with the prescriber to maintain mood stability or control of psychotic symptoms. 4